New EASL clinical practice guidelines on the management of hepatitis B virus

April 20, 2017, European Association for the Study of the Liver
Electron micrograph of hepatitis B virus. Credit: Centers for Disease Control and Prevention

The European Association for the Study of the Liver (EASL) today published their revised Clinical Practice Guidelines (CPGs) on the management of Hepatitis B virus (HBV) infection. The CPGs, which will also be presented in a session at The International Liver Congress 2017 in Amsterdam, The Netherlands, are designed to help physicians and healthcare providers optimise the management of patients with either acute or chronic HBV.

The new EASL HBV CPGs are the first international guidelines to include the new antiviral drug tenofovir alafenamide (TAF), as well as the latest scientific evidence on stopping antiviral therapy in distinct patient populations on long-term treatment.

HBV infection remains a global public health burden with changing epidemiology due to several factors including vaccination policies and migration. All patients with chronic HBV are at increased risk of progression to cirrhosis and hepatocellular carcinoma (HCC), depending on host and viral factors. The main goal of therapy is to improve survival and quality of life by preventing disease progression, and consequently HCC development. The induction of long-term suppression of HBV replication represents the main endpoint of current treatment strategies, while loss of HBsAg (a surface antigen of HBV which indicates current infection) is an optimal endpoint.

"Hepatitis B virus infections are major health threats that affect about 240 million individuals worldwide. The updated EASL guidelines integrate the latest scientific advances on diagnosis and therapy of Hepatitis B, thereby providing clear guidance to clinicians and patients for the management of this potentially life-threatening disease," said Prof Frank Tacke, member of the Clinical Practice Guideline panel and EASL Governing Board Member.

Based on an extensive systematic review of the most current literature by a panel of leading global experts, the updated HBV CPGs provide:

  • New definitions of disease phases that will better guide clinicians on treatment indications
  • Expanded indications for initiating treatment in order to prevent mother-to-child transmission, based on the latest scientific evidence
  • Clear cut recommendations for special patient populations (e.g., children, extrahepatic disease manifestations, prevention of HBV re-activation)
  • Practical rules for response-guided therapy in receiving pegylated interferon for HBV

The guidelines will be published in the official journal of EASL, the Journal of Hepatology (Vol. 67 Issue. 2, August 2017) and presented during a session at The International Liver CongressTM 2017 on Thursday, 20 April 2017, from 12:30 - 13:15, in Hall 5.

Explore further: European countries restrict access to life-saving treatment for hepatitis C

Related Stories

European countries restrict access to life-saving treatment for hepatitis C

April 20, 2017
Data presented today demonstrate that there are considerable restrictions in the reimbursement of direct-acting antiviral (DAA) therapy across European countries, particularly with respect to the severity of liver fibrosis ...

New clinical practice guidelines on alcoholic liver disease published

April 19, 2012
EASL today announced the publication of a new clinical practice guideline (CPG) in the area of Alcoholic Liver Disease (ALD), bringing the number of CPGs published to date to eight.

EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus

December 9, 2013
The European Association for the Study of the Liver (EASL) today publishes their revised Clinical Practice Guidelines (CPGs) on the management of hepatitis C virus infection (HCV) (1). The EASL guidelines, which supersede ...

EASL publishes online recommendations on the management of hepatitis C

April 9, 2014
The European Association for the Study of the Liver (EASL) will this week be announcing new on-line recommendations on the management of hepatitis C (HCV) at the International Liver Congress (ILC). These EASL recommendations ...

Study demonstrates benefits of existing treatment for hepatitis D patients

April 15, 2016
New research presented today shows that interferon alpha (IFNa) based therapies are effective in suppressing disease progression in a severe form of chronic viral hepatitis, Hepatitis delta.

EASL-EORTC publish joint clinical practice guidelines on hepatocellular carcinoma management

March 15, 2012
The European Association for the Study of the Liver (EASL) and the European Organisation for Research and Treatment of Cancer (EORTC) today publish their first joint Clinical Practice Guidelines (CPGs) on the management of ...

Recommended for you

Building better tiny kidneys to test drugs and help people avoid dialysis

February 16, 2018
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.

Expanding Hepatitis C testing to all adults is cost-effective and improves outcomes

February 16, 2018
According to a new study, screening all adults for hepatitis C (HCV) is a cost-effective way to improve clinical outcomes of HCV and identify more infected people compared to current recommendations. Using a simulation model, ...

Study suggests expanded range for emerging tick-borne disease

February 16, 2018
Human cases of Borrelia miyamotoi, a tick-borne infection with some similarities to Lyme disease, were discovered in the eastern United States less than a decade ago. Now new research led by the Yale School of Public Health ...

Flu shot only 36 percent effective, making bad year worse (Update)

February 15, 2018
The flu vaccine is doing a poor job protecting older Americans and others against the bug that's causing most illnesses.

IFN-mediated immunity to influenza A virus infection influenced by RIPK3 protein

February 15, 2018
Each year, influenza kills half a million people globally with the elderly and very young most often the victims. In fact, the Centers for Disease Control and Prevention reported 37 children have died in the United States ...

A new class of drug to treat herpes simplex virus-1 infection

February 14, 2018
For patients with the herpes simplex-1 virus (HSV-1), there are just a handful of drugs available to treat the painful condition that can affect the eyes, mouth and genitals.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.